Most Claims Stand In Securities Suit Over Vioxx Risks

Law360, New York (August 9, 2011, 3:09 PM EDT) -- A New Jersey federal judge on Monday preserved most claims against Merck & Co. Inc. in a securities class action filed by employee investors claiming the company inflated stock prices by downplaying a possible link between heart attack risks and its shelved painkiller Vioxx.

The plaintiffs in the multidistrict litigation — participants in Merck's various retirement benefits plans — allege that the company and its directors breached their duties under the Employee Retirement Income Security Act by concealing information about Vioxx, artificially inflating the value of...
To view the full article, register now.